Literature DB >> 24829411

Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo.

Kirsten Neubert1, Christian H K Lehmann1, Lukas Heger1, Anna Baranska1, Anna Maria Staedtler1, Veit R Buchholz2, Sayuri Yamazaki3, Gordon F Heidkamp1, Nathalie Eissing1, Henry Zebroski4, Michel C Nussenzweig5, Falk Nimmerjahn6, Diana Dudziak7.   

Abstract

Dendritic cells (DCs) are central modulators of immune responses and, therefore, interesting target cells for the induction of antitumor immune responses. Ag delivery to select DC subpopulations via targeting Abs to DC inhibitory receptor 2 (DCIR2, clone 33D1) or to DEC205 was shown to direct Ags specifically to CD11c(+)CD8(-) or CD11c(+)CD8(+) DCs, respectively, in vivo. In contrast to the increasing knowledge about the induction of immune responses by efficiently cross-presenting CD11c(+)CD8(+) DCs, little is known about the functional role of Ag-presenting CD11c(+)CD8(-) DCs with regard to the initiation of protective immune responses. In this study, we demonstrate that Ag targeting to the CD11c(+)CD8(-) DC subpopulation in the presence of stimulating anti-CD40 Ab and TLR3 ligand polyinosinic-polycytidylic acid induces protective responses against rapidly growing tumor cells in naive animals under preventive and therapeutic treatment regimens in vivo. Of note, this immunization protocol induced a mixed Th1/Th2-driven immune response, irrespective of which DC subpopulation initially presented the Ag. Our results provide important information about the role of CD11c(+)CD8(-) DCs, which have been considered to be less efficient at cross-presenting Ags, in the induction of protective antitumor immune responses.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24829411     DOI: 10.4049/jimmunol.1300975

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Ex vivo induction of antitumor DEC-205+ CD11c+ cells in a murine neuroblastoma model by co-stimulation with doxorubicin, lipopolysaccharide and interleukin-4.

Authors:  Seiichiro Inoue; Yumiko Setoyama; Yoshifumi Beck; Daiki Kitagawa; Akio Odaka
Journal:  Biomed Rep       Date:  2015-11-20

2.  DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes.

Authors:  Jeffrey D Price; Chie Hotta-Iwamura; Yongge Zhao; Nicole M Beauchamp; Kristin V Tarbell
Journal:  Diabetes       Date:  2015-06-12       Impact factor: 9.461

3.  Distinct oxysterol requirements for positioning naïve and activated dendritic cells in the spleen.

Authors:  Erick Lu; Eric V Dang; Jeffrey G McDonald; Jason G Cyster
Journal:  Sci Immunol       Date:  2017-04-07

4.  The aryl hydrocarbon receptor instructs the immunomodulatory profile of a subset of Clec4a4+ eosinophils unique to the small intestine.

Authors:  Wei-Le Wang; Jun Kasamatsu; Satoru Joshita; Susan Gilfillan; Blanda Di Luccia; Santosh K Panda; Do-Hyun Kim; Pritesh Desai; Jennifer K Bando; Stanley Ching-Cheng Huang; Kentaro Yomogida; Hitomi Hoshino; Mana Fukushima; Elizabeth A Jacobsen; Steven J Van Dyken; Christiane Ruedl; Marina Cella; Marco Colonna
Journal:  Proc Natl Acad Sci U S A       Date:  2022-06-02       Impact factor: 12.779

5.  IL-28B down-regulates regulatory T cells but does not improve the protective immunity following tuberculosis subunit vaccine immunization.

Authors:  Yanping Luo; Xingming Ma; Xun Liu; Xiaoling Lu; Hongxia Niu; Hongjuan Yu; Chunxiang Bai; Jinxiu Peng; Qiaoyang Xian; Yong Wang; Bingdong Zhu
Journal:  Int Immunol       Date:  2015-10-31       Impact factor: 4.823

Review 6.  The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases.

Authors:  Jeffrey D Price; Kristin V Tarbell
Journal:  Front Immunol       Date:  2015-06-15       Impact factor: 7.561

Review 7.  Transcriptional Control of Dendritic Cell Development.

Authors:  Theresa L Murphy; Gary E Grajales-Reyes; Xiaodi Wu; Roxane Tussiwand; Carlos G Briseño; Arifumi Iwata; Nicole M Kretzer; Vivek Durai; Kenneth M Murphy
Journal:  Annu Rev Immunol       Date:  2015-12-23       Impact factor: 28.527

Review 8.  Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.

Authors:  Cleo Goyvaerts; Karine Breckpot
Journal:  J Immunol Res       Date:  2015-10-25       Impact factor: 4.818

9.  Clec4A4 is a regulatory receptor for dendritic cells that impairs inflammation and T-cell immunity.

Authors:  Tomofumi Uto; Tomohiro Fukaya; Hideaki Takagi; Keiichi Arimura; Takeshi Nakamura; Naoya Kojima; Bernard Malissen; Katsuaki Sato
Journal:  Nat Commun       Date:  2016-04-12       Impact factor: 14.919

10.  Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8+CD11c+ PD-1lo Effector T Cells.

Authors:  Nicolas Goudin; Pascal Chappert; Jérome Mégret; David-Alexandre Gross; Benedita Rocha; Orly Azogui
Journal:  PLoS One       Date:  2016-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.